Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-03

AUTHORS

F O Nestle, S Alijagic, M Gilliet, Y Sun, S Grabbe, R Dummer, G Burg, D Schadendorf

ABSTRACT

Melanoma is the main cause of death in patients with skin cancer. Cytotoxic T lymphocytes (CTLs) attack melanoma cells in an HLA-restricted and tumor antigen-specific manner. Several melanoma-associated tumor antigens have been identified. These antigens are suitable candidates for a vaccination therapy of melanoma. Dendritic cells (DCs) are antigen-presenting cells (APCs) specialized for the induction of a primary T-cell response. Mouse studies have demonstrated the potent capacity of DCs to induce antitumor immunity. In the present clinical pilot study, DCs were generated in the presence of granulocyte/macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL-4) and were pulsed with tumor lysate or a cocktail of peptides known to be recognized by CTLs, depending on the patient's HLA haplotype. Keyhole limpet hemocyanin (KLH) was added as a CD4 helper antigen and immunological tracer molecule. Sixteen patients with advanced melanoma were immunized on an outpatient basis. Vaccination was well tolerated. No physical sign of autoimmunity was detected in any of the patients. DC vaccination induced delayed-type hypersensitivity (DTH) reactivity toward KLH in all patients, as well as a positive DTH reaction to peptide-pulsed DCs in 11 patients. Recruitment of peptide-specific CTLs to the DTH challenge site was also demonstrated. Therefore, antigen-specific immunity was induced during DC vaccination. Objective responses were evident in 5 out of 16 evaluated patients (two complete responses, three partial responses) with regression of metastases in various organs (skin, soft tissue, lung, pancreas) and one additional minor response. These data indicate that vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma. Further studies are necessary to demonstrate clinical effectiveness and impact on the survival of melanoma patients. More... »

PAGES

328-332

Journal

TITLE

Nature Medicine

ISSUE

3

VOLUME

4

Author Affiliations

Related Patents

  • Use Of Allogeneic Cell Lines To Load Antigen-Presenting Cells To Elicit Or Eliminate Immune Responses
  • Rapid One-Step Method For Generation Of Antigen Loaded Dendritic Cell Vaccine From Precursors
  • Tumor Associated Antigen, Peptides Thereof, And Use Of Same As Anti-Tumor Vaccines
  • Method Of Treating Malignancies Through Induction Of Blood Immune Responses
  • A Medicament For Use In A Method Of Inducing Or Extending A Cellular Cytotoxic Immune Response
  • Modified Polynucleotides For The Production Of Secreted Proteins
  • Dendritic Cells Generated Using Gm-Csf And Interferon Alpha And Loaded With Heat-Treated And Killed Cancer Cells
  • Multi-Antigenic Alphavirus Replicon Particles And Methods
  • Packaging Of Immunostimulatory Substances Into Virus-Like Particles: Method Of Preparation And Use
  • Method For Activation Treatment Of Antigen-Presenting Cell
  • Melanoma Vaccine And Methods Of Making And Using Same
  • Method Of Inducing A Ctl Response
  • Engineered Nucleic Acids Encoding A Modified Erythropoietin And Their Expression
  • A Method Of Treating Cancer Cells To Create A Modified Cancer Cell That Provokes An Immunogenic Response
  • Controlled Delivery Of Tlr Agonists In Structural Polymeric Devices
  • Application Of Mrna For Use As A Therapeutic Against Tumor Diseases
  • Polypeptide
  • Injectable Cryogel Vaccine Devices And Methods Of Use Thereof
  • Agents And Methods To Elicit Anti-Tumor Immune Response
  • Anticancer Agent Containing Dendritic Cell Having Rna Virus Transferred Thereinto
  • Adenoviral Expression Vector Comprising A Cd40l Fusion Protein Adapted To Elicit Cellular Immunity
  • Application Of Mrna For Use As A Therapeutic Agent For Tumorous Diseases
  • Modified Polynucleotides For The Production Of Biologics And Proteins Associated With Human Disease
  • Modified Polynucleotides For Treating Galactosylceramidase Protein Deficiency
  • Bacterial Ribonucleic Acid Cell Wall Compositions And Methods Of Making And Using Them
  • Scaffolds For Cell Transplantation
  • Modified Polynucleotides Encoding Granulysin
  • Modification Of Exosomal Components For Use As A Vaccine
  • Modified Polynucleotides Encoding Apoptosis Inducing Factor 1
  • Modified Polynucleotides For The Production Of Nuclear Proteins
  • Modified Polynucleotides Encoding Cited4
  • Modified Polynucleotides Encoding Septin-4
  • Mhc Class Ii Restricted T Cell Epitopes From The Cancer Antigen, Ny Eso-1
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Composition And Method For Inducing And Enhancing A Telomerase Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte Response
  • Polypeptide
  • Administration Of 5t4 Antigen And Immune Response Of Cells Expressing 5t4 And Cea Antigens
  • Mhc Class I Peptide Epitopes From The Human 5t4 Tumor-Associated Antigen
  • Application Of Mrna For Use As A Therapeutic Against Tumour Diseases
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Application Of Mrna For Use As A Therapeutic Against Tumour Diseases
  • Kidney-Specific Tumor Vaccine Directed Against Kidney Tumor Antigen G-250
  • Platform Of Dendritic Cell (Dc)-Based Vaccination
  • Polypeptide
  • Immunostimulatory Nucleic Acid Molecules For Activating Dendritic Cells
  • A Medicament For Use In A Method Of Inducing Or Extending A Cellular Cytotoxic Immune Response
  • Modified Polynucleotides For Treating Protein Deficiency
  • Method Of Inducing And/Or Enhancing An Immune Response To Tumor Antigens
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Modified Polynucleotides For The Production Of Proteins Associated With Human Disease
  • Delivery And Formulation Of Engineered Nucleic Acids
  • Chimeric Polypeptide Comprising The Fragment B Of Shiga Toxin And Peptides Of Therapeutic Interest
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Ctl Inducer Composition
  • Method Of Treating Cancer Cells To Create A Modified Cancer Cell That Provokes An Immunogenic Response
  • Modified Polynucleotides Encoding Copper Metabolism (Murr1) Domain Containing 1
  • Injectable Preformed Macroscopic 3-Dimensional Scaffolds For Minimally Invasive Administration
  • Mesoporous Silica Compositions For Modulating Immune Responses
  • Mhc Class Ii Epitopes Of 5t4 Antigen
  • Mature Type-1 Polarized Dendritic Cells With Enhanced Il-12 Production And Methods Of Serum-Free Production And Use
  • Composition Comprising An Adenoviral Expression Vector Comprising A Cd40l Fusion Protein For Generating Immune Responses
  • Intra-Tumoral Administration Of Il-12 Encoding Nucleic Acid Molecules
  • Method Of Inducing A Ctl Response
  • Human Paris-1 Antigen And Nucleic Acids: Diagnostic And Therapeutic Uses
  • Cellular Vaccines And Immunotherapeutics And Methods For Their Preparation
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Modified Dendritic Cells Having Enhanced Survival And Immunogenicity And Related Compositions And Methods
  • Programming Of Cells For Tolerogenic Therapies
  • Formulation And Delivery Of Plga Microspheres
  • Application Of Mrna For Use As A Therapeutic Against Tumour Diseases
  • Compositions And Methods Of Altering Cholesterol Levels
  • Modified Polynucleotides Encoding Basic Helix-Loop-Helix Family Member E41
  • Modified Polynucleotides For The Production Of Proteins
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Programming Of Cells For Tolerogenic Therapies
  • Verotoxin B Subunit For Immunization
  • Modified Polynucleotides For The Production Of Oncology-Related Proteins And Peptides
  • Ctl Inducer Composition
  • Modified Polynucleotides For The Production Of G-Csf
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Packaging Of Immunostimulatory Substances Into Virus-Like Particles: Method Of Preparation And Use
  • Terminally Modified Rna
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Bacterial Ribonucleic Acid Cell Wall Compositions And Methods Of Making And Using Them
  • Novel Mhc Class Ii Restricted T Cell Epitopes From The Cancer Antigen, Ny Eso-1
  • Methods For Enhancing Antigen Presentation
  • Method Of Treating Malignancies Through Induction Of Blood Immune Responses
  • Therapeutic Cancer Vaccine
  • Engineered Nucleic Acids And Methods Of Use Thereof
  • Modified Polynucleotides For The Production Of Cosmetic Proteins And Peptides
  • Method Of Inducing A Ctl Response
  • Application Of Mrna For Use As A Therapeutic Against Tumour Diseases
  • Modified Polynucleotides Encoding Siah E3 Ubiquitin Protein Ligase 1
  • Method Of Inducing A Ctl Response
  • Methods For Treating Cancer Using Prostate Specific Antigen And Tumor Endothelial Marker Peptides
  • Dlin-Kc2-Dma Lipid Nanoparticle Delivery Of Modified Polynucleotides
  • A Medicament For Use In A Method Of Inducing Or Extending A Cellular Cytotoxic Immune Response
  • Application Of Mrna For Use As A Therapeutic Against Tumour Diseases
  • Modified Polynucleotides For The Production Of Secreted Proteins
  • Tumour Rejection Antigens
  • Ctage Gene Family
  • Nucleic Acid Molecule Encoding A Mhc Class I Peptide Epitope From The Human 5t4 Tumor-Associated Antigen And Vector Comprising The Nucleic Acid Molecule
  • Kidney-Specific Tumor Vaccine Directed Against Kidney Tumor Antigen G-250
  • Modified Polynucleotides Encoding Hepatitis A Virus Cellular Receptor 2
  • In Vivo Production Of Proteins
  • Controlled Delivery Of Tlr3 Agonists In Structural Polymeric Devices
  • Polypeptide
  • Modified Polynucleotides For The Production Of Proteins
  • Method For Producing A Protein Of Interest In A Primate
  • Methods Of Generating Immune Responses With Compositions Comprising An Adenoviral Expression Vector Comprising A Cd40l Fusion Protein
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Kidney-Specific Tumor Vaccine Directed Against Kidney Tumor Antigen G-250
  • Agents And Methods To Elicit Anti-Tumor Immune Response
  • Modified Polynucleotides For The Production Of Cytoplasmic And Cytoskeletal Proteins
  • Modified Polynucleotides For The Production Of Cytoplasmic And Cytoskeletal Proteins
  • A Method Of Treating Cancer Cells To Create A Modified Cancer Cell That Provokes An Immunogenic Response
  • Modified Polynucleotides Encoding Aquaporin-5
  • Modified Polynucleotides For The Production Of Proteins Associated With Blood And Lymphatic Disorders
  • Novel Mhc Class Ii Restricted T Cell Epitopes From The Cancer Antigen, Ny Eso-1
  • Novel Mhc Class Ii Restricted T Cell Epitopes From The Cancer Antigen, Ny Eso-1
  • A Method Of Treating Cancer Cells To Create A Modified Cancer Cell That Provokes An Immunogenic Response
  • Scaffolds For Cell Collection Or Elimination
  • Kidney Specific Tumor Vaccine Directed Against Kidney Tumor Antigen G-250
  • Modified Polynucleotides Encoding Aryl Hydrocarbon Receptor Nuclear Translocator
  • Modified Polynucleotides For The Production Of Proteins Associated With Blood And Lymphatic Disorders
  • Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof
  • Composition And Method For Inducing And Enhancing A Telomerase Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte Response
  • Tumor Rejection Antigens
  • Bacterial Ribonucleic Acid Cell Wall Compositions And Methods Of Making And Using Them
  • Chimeric Polypeptide Comprising The Fragment B Of Shiga Toxin And Peptides Of Therapeutic Interest
  • Split Dose Administration
  • Bacterial Ribonucleic Acid Cell Wall Compositions And Methods Of Making And Using Them
  • Modified Polynucleotides For The Production Of Biologics And Proteins Associated With Human Disease
  • Formulation And Delivery Of Plga Microspheres
  • Peptide Vaccine Comprising Mutant Ras Peptide And Chemotherapeutic Agent
  • Methods And Products For Inducing Mucosal Immunity
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nm0398-328

    DOI

    http://dx.doi.org/10.1038/nm0398-328

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1017994921

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9500607


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antigens, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cancer Vaccines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dendritic Cells", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypersensitivity, Delayed", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lung Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peptides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Skin Tests", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "T-Lymphocytes, Cytotoxic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tomography", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vaccination", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University of Zurich", 
              "id": "https://www.grid.ac/institutes/grid.7400.3", 
              "name": [
                "Department of Dermatology, University of Zurich Medical School, Switzerland."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nestle", 
            "givenName": "F O", 
            "id": "sg:person.01221556472.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221556472.47"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Alijagic", 
            "givenName": "S", 
            "id": "sg:person.01322161574.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322161574.40"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Gilliet", 
            "givenName": "M", 
            "id": "sg:person.0603753220.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603753220.39"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Sun", 
            "givenName": "Y", 
            "id": "sg:person.0647733434.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647733434.04"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Grabbe", 
            "givenName": "S", 
            "id": "sg:person.01160620200.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160620200.14"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Dummer", 
            "givenName": "R", 
            "id": "sg:person.01301465365.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301465365.05"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Burg", 
            "givenName": "G", 
            "id": "sg:person.01112227263.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112227263.30"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Schadendorf", 
            "givenName": "D", 
            "id": "sg:person.01117256754.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117256754.05"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1073/pnas.92.17.8078", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001781671"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1295-1297", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003113140", 
              "https://doi.org/10.1038/nm1295-1297"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1146/annurev.immunol.14.1.333", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004359095"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1146/annurev.iy.09.040191.001415", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005122639"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.186.1.65", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005909860"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.186.1.65", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005909860"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0167-5699(96)80544-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007162540"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/360258a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009029259", 
              "https://doi.org/10.1038/360258a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.183.1.317", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010430085"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830240317", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018990595"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.183.4.1357", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020885624"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830251117", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032466083"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.179.4.1109", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032628043"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0196-52", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037938818", 
              "https://doi.org/10.1038/nm0196-52"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.180.1.83", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038172184"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0167-5699(97)84664-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038821180"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.183.1.87", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040566467"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1084/jem.183.1.283", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046841430"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ijc.2910630622", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049260773"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0167-5699(95)80125-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053696122"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1126/science.8493532", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1062655804"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1078881751", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/oxfordjournals.bmb.a072980", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1082409691"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082878812", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1083061979", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1998-03", 
        "datePublishedReg": "1998-03-01", 
        "description": "Melanoma is the main cause of death in patients with skin cancer. Cytotoxic T lymphocytes (CTLs) attack melanoma cells in an HLA-restricted and tumor antigen-specific manner. Several melanoma-associated tumor antigens have been identified. These antigens are suitable candidates for a vaccination therapy of melanoma. Dendritic cells (DCs) are antigen-presenting cells (APCs) specialized for the induction of a primary T-cell response. Mouse studies have demonstrated the potent capacity of DCs to induce antitumor immunity. In the present clinical pilot study, DCs were generated in the presence of granulocyte/macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL-4) and were pulsed with tumor lysate or a cocktail of peptides known to be recognized by CTLs, depending on the patient's HLA haplotype. Keyhole limpet hemocyanin (KLH) was added as a CD4 helper antigen and immunological tracer molecule. Sixteen patients with advanced melanoma were immunized on an outpatient basis. Vaccination was well tolerated. No physical sign of autoimmunity was detected in any of the patients. DC vaccination induced delayed-type hypersensitivity (DTH) reactivity toward KLH in all patients, as well as a positive DTH reaction to peptide-pulsed DCs in 11 patients. Recruitment of peptide-specific CTLs to the DTH challenge site was also demonstrated. Therefore, antigen-specific immunity was induced during DC vaccination. Objective responses were evident in 5 out of 16 evaluated patients (two complete responses, three partial responses) with regression of metastases in various organs (skin, soft tissue, lung, pancreas) and one additional minor response. These data indicate that vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma. Further studies are necessary to demonstrate clinical effectiveness and impact on the survival of melanoma patients.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1038/nm0398-328", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1113716", 
            "issn": [
              "1078-8956", 
              "1546-170X"
            ], 
            "name": "Nature Medicine", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "4"
          }
        ], 
        "name": "Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells", 
        "pagination": "328-332", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "55bd6b27a8d3ad94c879b544d8bedbe2c6e3abc67f568324c2a0d4cfbd665f92"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9500607"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "9502015"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nm0398-328"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1017994921"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nm0398-328", 
          "https://app.dimensions.ai/details/publication/pub.1017994921"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T14:48", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000434.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://www.nature.com/nm/journal/v4/n3/full/nm0398-328.html"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nm0398-328'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nm0398-328'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nm0398-328'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nm0398-328'


     

    This table displays all metadata directly associated to this object as RDF triples.

    251 TRIPLES      21 PREDICATES      70 URIs      38 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nm0398-328 schema:about N07b279206f2d47ff8d53198e430d3b51
    2 N0c83c186987a447ca0889961d0583987
    3 N14191f97d0d5496db96a0f8898da3678
    4 N3b54293d1e7c4d898fbbeacde1456789
    5 N406cdc3699564ff0a14da78af90e177a
    6 N507702b9f763405e9bea0313313fd449
    7 N5d93b9fd32ab4812adc66a230b208ab5
    8 N607dd1950ac34d32a9f241fbd45d21f8
    9 N6b2d5451becc40b2b94cd6d1abe94c4b
    10 N8373e66b5f644a22acb1a20159ac7f57
    11 N85615bd3792048ebad34fd6fd65c2dda
    12 N981733bbbc6c406da31756cd0f3e1740
    13 Nb81e5cdf743a4cfebc9b30b5ae616d74
    14 Nce2b6a89b4e84e328ebd9a9c6659fa70
    15 Nd4ac4fe60785433a8b8bf00601eb3fca
    16 Nde8946df9f5e45d8bc090e258d8dca28
    17 Nfc52ee0ae8294e0e985f5291866277e6
    18 anzsrc-for:11
    19 anzsrc-for:1107
    20 schema:author N9c293c85c32f4a26bdb6d054f82ac836
    21 schema:citation sg:pub.10.1038/360258a0
    22 sg:pub.10.1038/nm0196-52
    23 sg:pub.10.1038/nm1295-1297
    24 https://app.dimensions.ai/details/publication/pub.1078881751
    25 https://app.dimensions.ai/details/publication/pub.1082878812
    26 https://app.dimensions.ai/details/publication/pub.1083061979
    27 https://doi.org/10.1002/eji.1830240317
    28 https://doi.org/10.1002/eji.1830251117
    29 https://doi.org/10.1002/ijc.2910630622
    30 https://doi.org/10.1016/0167-5699(95)80125-1
    31 https://doi.org/10.1016/0167-5699(96)80544-5
    32 https://doi.org/10.1016/s0167-5699(97)84664-6
    33 https://doi.org/10.1073/pnas.92.17.8078
    34 https://doi.org/10.1084/jem.179.4.1109
    35 https://doi.org/10.1084/jem.180.1.83
    36 https://doi.org/10.1084/jem.183.1.283
    37 https://doi.org/10.1084/jem.183.1.317
    38 https://doi.org/10.1084/jem.183.1.87
    39 https://doi.org/10.1084/jem.183.4.1357
    40 https://doi.org/10.1084/jem.186.1.65
    41 https://doi.org/10.1093/oxfordjournals.bmb.a072980
    42 https://doi.org/10.1126/science.8493532
    43 https://doi.org/10.1146/annurev.immunol.14.1.333
    44 https://doi.org/10.1146/annurev.iy.09.040191.001415
    45 schema:datePublished 1998-03
    46 schema:datePublishedReg 1998-03-01
    47 schema:description Melanoma is the main cause of death in patients with skin cancer. Cytotoxic T lymphocytes (CTLs) attack melanoma cells in an HLA-restricted and tumor antigen-specific manner. Several melanoma-associated tumor antigens have been identified. These antigens are suitable candidates for a vaccination therapy of melanoma. Dendritic cells (DCs) are antigen-presenting cells (APCs) specialized for the induction of a primary T-cell response. Mouse studies have demonstrated the potent capacity of DCs to induce antitumor immunity. In the present clinical pilot study, DCs were generated in the presence of granulocyte/macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL-4) and were pulsed with tumor lysate or a cocktail of peptides known to be recognized by CTLs, depending on the patient's HLA haplotype. Keyhole limpet hemocyanin (KLH) was added as a CD4 helper antigen and immunological tracer molecule. Sixteen patients with advanced melanoma were immunized on an outpatient basis. Vaccination was well tolerated. No physical sign of autoimmunity was detected in any of the patients. DC vaccination induced delayed-type hypersensitivity (DTH) reactivity toward KLH in all patients, as well as a positive DTH reaction to peptide-pulsed DCs in 11 patients. Recruitment of peptide-specific CTLs to the DTH challenge site was also demonstrated. Therefore, antigen-specific immunity was induced during DC vaccination. Objective responses were evident in 5 out of 16 evaluated patients (two complete responses, three partial responses) with regression of metastases in various organs (skin, soft tissue, lung, pancreas) and one additional minor response. These data indicate that vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma. Further studies are necessary to demonstrate clinical effectiveness and impact on the survival of melanoma patients.
    48 schema:genre research_article
    49 schema:inLanguage en
    50 schema:isAccessibleForFree false
    51 schema:isPartOf N2fdc6e134ce349ab83a19a34102bb8f8
    52 N5c8dc0bb21744a62beeff72437c680db
    53 sg:journal.1113716
    54 schema:name Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
    55 schema:pagination 328-332
    56 schema:productId N02ee183e53e94da0ac00dde6559f6b2a
    57 N1823f0690cab46618a51f16c77fcc347
    58 N196d5f253bfb4c6ebd510271de1f99a5
    59 Na98bebb997484b7d9a87a40ea3c06855
    60 Naebd82c9852f472885e5a27a813144bb
    61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017994921
    62 https://doi.org/10.1038/nm0398-328
    63 schema:sdDatePublished 2019-04-10T14:48
    64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    65 schema:sdPublisher Nc8559999fc9b47dfa83aecdb58de885d
    66 schema:url http://www.nature.com/nm/journal/v4/n3/full/nm0398-328.html
    67 sgo:license sg:explorer/license/
    68 sgo:sdDataset articles
    69 rdf:type schema:ScholarlyArticle
    70 N02ee183e53e94da0ac00dde6559f6b2a schema:name nlm_unique_id
    71 schema:value 9502015
    72 rdf:type schema:PropertyValue
    73 N07b279206f2d47ff8d53198e430d3b51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    74 schema:name Middle Aged
    75 rdf:type schema:DefinedTerm
    76 N0c83c186987a447ca0889961d0583987 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    77 schema:name Tomography
    78 rdf:type schema:DefinedTerm
    79 N14191f97d0d5496db96a0f8898da3678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    80 schema:name Hypersensitivity, Delayed
    81 rdf:type schema:DefinedTerm
    82 N1823f0690cab46618a51f16c77fcc347 schema:name pubmed_id
    83 schema:value 9500607
    84 rdf:type schema:PropertyValue
    85 N196d5f253bfb4c6ebd510271de1f99a5 schema:name doi
    86 schema:value 10.1038/nm0398-328
    87 rdf:type schema:PropertyValue
    88 N2b8010684f6647abb9d7569dbe75c36f rdf:first sg:person.01301465365.05
    89 rdf:rest Nc2763d001c7e41f6885be3e469c5e94e
    90 N2fdc6e134ce349ab83a19a34102bb8f8 schema:volumeNumber 4
    91 rdf:type schema:PublicationVolume
    92 N365a5052a3f14da6a01e97df5de4e444 rdf:first sg:person.01160620200.14
    93 rdf:rest N2b8010684f6647abb9d7569dbe75c36f
    94 N3b54293d1e7c4d898fbbeacde1456789 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Male
    96 rdf:type schema:DefinedTerm
    97 N406cdc3699564ff0a14da78af90e177a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Lung Neoplasms
    99 rdf:type schema:DefinedTerm
    100 N507702b9f763405e9bea0313313fd449 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Peptides
    102 rdf:type schema:DefinedTerm
    103 N5c8dc0bb21744a62beeff72437c680db schema:issueNumber 3
    104 rdf:type schema:PublicationIssue
    105 N5d93b9fd32ab4812adc66a230b208ab5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Melanoma
    107 rdf:type schema:DefinedTerm
    108 N607dd1950ac34d32a9f241fbd45d21f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name T-Lymphocytes, Cytotoxic
    110 rdf:type schema:DefinedTerm
    111 N68ef9c7a3bd643f08b127df3f3d99cd0 rdf:first sg:person.01117256754.05
    112 rdf:rest rdf:nil
    113 N6b2d5451becc40b2b94cd6d1abe94c4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Skin Tests
    115 rdf:type schema:DefinedTerm
    116 N8373e66b5f644a22acb1a20159ac7f57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Aged
    118 rdf:type schema:DefinedTerm
    119 N85615bd3792048ebad34fd6fd65c2dda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Cancer Vaccines
    121 rdf:type schema:DefinedTerm
    122 N981733bbbc6c406da31756cd0f3e1740 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Vaccination
    124 rdf:type schema:DefinedTerm
    125 N9c293c85c32f4a26bdb6d054f82ac836 rdf:first sg:person.01221556472.47
    126 rdf:rest Naa5557865b00476cbf405186f47940be
    127 Na98bebb997484b7d9a87a40ea3c06855 schema:name readcube_id
    128 schema:value 55bd6b27a8d3ad94c879b544d8bedbe2c6e3abc67f568324c2a0d4cfbd665f92
    129 rdf:type schema:PropertyValue
    130 Naa5557865b00476cbf405186f47940be rdf:first sg:person.01322161574.40
    131 rdf:rest Ne7163a2b50944040ac3521f2fba2911a
    132 Naebd82c9852f472885e5a27a813144bb schema:name dimensions_id
    133 schema:value pub.1017994921
    134 rdf:type schema:PropertyValue
    135 Nb81e5cdf743a4cfebc9b30b5ae616d74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Humans
    137 rdf:type schema:DefinedTerm
    138 Nc2763d001c7e41f6885be3e469c5e94e rdf:first sg:person.01112227263.30
    139 rdf:rest N68ef9c7a3bd643f08b127df3f3d99cd0
    140 Nc8559999fc9b47dfa83aecdb58de885d schema:name Springer Nature - SN SciGraph project
    141 rdf:type schema:Organization
    142 Nce2b6a89b4e84e328ebd9a9c6659fa70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Antigens, Neoplasm
    144 rdf:type schema:DefinedTerm
    145 Nd4ac4fe60785433a8b8bf00601eb3fca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Dendritic Cells
    147 rdf:type schema:DefinedTerm
    148 Nd754d2fdbc42450c8ae3f3ca03b5260e rdf:first sg:person.0647733434.04
    149 rdf:rest N365a5052a3f14da6a01e97df5de4e444
    150 Nde8946df9f5e45d8bc090e258d8dca28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Adult
    152 rdf:type schema:DefinedTerm
    153 Ne7163a2b50944040ac3521f2fba2911a rdf:first sg:person.0603753220.39
    154 rdf:rest Nd754d2fdbc42450c8ae3f3ca03b5260e
    155 Nfc52ee0ae8294e0e985f5291866277e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Female
    157 rdf:type schema:DefinedTerm
    158 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    159 schema:name Medical and Health Sciences
    160 rdf:type schema:DefinedTerm
    161 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    162 schema:name Immunology
    163 rdf:type schema:DefinedTerm
    164 sg:journal.1113716 schema:issn 1078-8956
    165 1546-170X
    166 schema:name Nature Medicine
    167 rdf:type schema:Periodical
    168 sg:person.01112227263.30 schema:familyName Burg
    169 schema:givenName G
    170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112227263.30
    171 rdf:type schema:Person
    172 sg:person.01117256754.05 schema:familyName Schadendorf
    173 schema:givenName D
    174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117256754.05
    175 rdf:type schema:Person
    176 sg:person.01160620200.14 schema:familyName Grabbe
    177 schema:givenName S
    178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160620200.14
    179 rdf:type schema:Person
    180 sg:person.01221556472.47 schema:affiliation https://www.grid.ac/institutes/grid.7400.3
    181 schema:familyName Nestle
    182 schema:givenName F O
    183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01221556472.47
    184 rdf:type schema:Person
    185 sg:person.01301465365.05 schema:familyName Dummer
    186 schema:givenName R
    187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301465365.05
    188 rdf:type schema:Person
    189 sg:person.01322161574.40 schema:familyName Alijagic
    190 schema:givenName S
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322161574.40
    192 rdf:type schema:Person
    193 sg:person.0603753220.39 schema:familyName Gilliet
    194 schema:givenName M
    195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603753220.39
    196 rdf:type schema:Person
    197 sg:person.0647733434.04 schema:familyName Sun
    198 schema:givenName Y
    199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647733434.04
    200 rdf:type schema:Person
    201 sg:pub.10.1038/360258a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009029259
    202 https://doi.org/10.1038/360258a0
    203 rdf:type schema:CreativeWork
    204 sg:pub.10.1038/nm0196-52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037938818
    205 https://doi.org/10.1038/nm0196-52
    206 rdf:type schema:CreativeWork
    207 sg:pub.10.1038/nm1295-1297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003113140
    208 https://doi.org/10.1038/nm1295-1297
    209 rdf:type schema:CreativeWork
    210 https://app.dimensions.ai/details/publication/pub.1078881751 schema:CreativeWork
    211 https://app.dimensions.ai/details/publication/pub.1082878812 schema:CreativeWork
    212 https://app.dimensions.ai/details/publication/pub.1083061979 schema:CreativeWork
    213 https://doi.org/10.1002/eji.1830240317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018990595
    214 rdf:type schema:CreativeWork
    215 https://doi.org/10.1002/eji.1830251117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032466083
    216 rdf:type schema:CreativeWork
    217 https://doi.org/10.1002/ijc.2910630622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049260773
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1016/0167-5699(95)80125-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053696122
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1016/0167-5699(96)80544-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007162540
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1016/s0167-5699(97)84664-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038821180
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.1073/pnas.92.17.8078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001781671
    226 rdf:type schema:CreativeWork
    227 https://doi.org/10.1084/jem.179.4.1109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032628043
    228 rdf:type schema:CreativeWork
    229 https://doi.org/10.1084/jem.180.1.83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038172184
    230 rdf:type schema:CreativeWork
    231 https://doi.org/10.1084/jem.183.1.283 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046841430
    232 rdf:type schema:CreativeWork
    233 https://doi.org/10.1084/jem.183.1.317 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010430085
    234 rdf:type schema:CreativeWork
    235 https://doi.org/10.1084/jem.183.1.87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040566467
    236 rdf:type schema:CreativeWork
    237 https://doi.org/10.1084/jem.183.4.1357 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020885624
    238 rdf:type schema:CreativeWork
    239 https://doi.org/10.1084/jem.186.1.65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005909860
    240 rdf:type schema:CreativeWork
    241 https://doi.org/10.1093/oxfordjournals.bmb.a072980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082409691
    242 rdf:type schema:CreativeWork
    243 https://doi.org/10.1126/science.8493532 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062655804
    244 rdf:type schema:CreativeWork
    245 https://doi.org/10.1146/annurev.immunol.14.1.333 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004359095
    246 rdf:type schema:CreativeWork
    247 https://doi.org/10.1146/annurev.iy.09.040191.001415 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005122639
    248 rdf:type schema:CreativeWork
    249 https://www.grid.ac/institutes/grid.7400.3 schema:alternateName University of Zurich
    250 schema:name Department of Dermatology, University of Zurich Medical School, Switzerland.
    251 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...